CHI3L1 and Alzheimer disease: Doing so allowed us to demonstrate that both GFAP and YKL-40 levels are not only elevated in patients on the AD continuum compared with CU, but also within the AD clinical spectrum, with higher levels seen in more advanced clinical stages.